Search Results for 'drug design'
Contract Service Directory Companies
Microsite Companies
Featured Companies
View All Buyers Guide Companies »
Contract Service Directory Categories
View All Categories »
-
Breaking News | Drug Development | Trials & Filings
AskBio Receives EC Orphan Drug Designation for AB-1003 LGMD Treatment
The drug will evaluate the safety, tolerability and efficacy of a single IV infusion of gene therapy in adult subjects.02.27.23
-
Breaking News | Drug Development | Drug Discovery | Industry News
Lilly, Schrödinger Enter Drug Design Collaboration
Schrödinger will receive as much as $425 million in discovery, development and commercial milestones for the optimization of small molecule compounds.10.10.22
-
Orphan Drug Designation in the US: Why does it matter?
Investigating how and why small pharmas should get onboard to help develop medicines effective in the treatment of orphan diseases.Katy Rudnick, Vice President and Head of US Regulatory Affairs, Boyds 05.02.22
-
Breaking News | Drug Development
Regenxbio Receives FDA Orphan Drug Designation for Potential Duchenne Treatment
Marks a milestone in the development of RGX-202 and highlights the need for potential new treatment options for patients with Duchenne.11.22.21
-
Breaking News | Drug Development
FDA Grants Orphan Drug Designation for Brain Cancer Drug Berubicin
Accelerates its development to treat malignant gliomas and provides CNS with the potential for market exclusivity.Contract Pharma Staff 06.11.20
-
Biologics, Proteins, Vaccines
The Evolution of the ADC Manufacturer
How CMDOs can rise to the occasionLisa McDermott and Jyothi Swamy, MilliporeSigma 04.01.20
-
Breaking News | Collaborations & Alliances | Drug Discovery | Industry News
XtalPi Collaborates with Porton
Combining AI algorithms with targeted experiments to solve bottleneck challenges in drug developmentContract Pharma Staff 03.12.20
-
Drug Development
-
Breaking News | Collaborations & Alliances | Drug Development | Industry News | R&D
Sosei Heptares, Takeda Enter R&D Partnership
Could be worth more than $1.2 billion and involves small molecules and biologics08.05.19
-
Trials & Filings
Mustang Bio’s AML Treatment Receives Orphan Drug Designation
MB-102 (CD123 CAR T) evaluated to treat AML and BPDCN07.30.19
-
Drug Discovery | Information Technology
Artificial Intelligence and Machine Learning in Healthcare
Because your summertime reading should make you a little uncomfortable.Ben Locwin, PhD, MBA, MS, Contributing Editor 07.15.19
-
Collaborations & Alliances | Drug Development
PhoreMost and C4X Discovery Announce Collaboration
Collaboration will initially accelerate C4X Discovery’s Parkinson’s disease pipeline06.25.19
-
Breaking News | Collaborations & Alliances | Drug Discovery | Information Technology
Merck KGaA, Iktos Enter AI Discovery Partnership
Collaboration gives Merck KGaA access to Iktos AI technology across three drug discovery projects03.14.19
-
Drug Development | Drug Discovery | Information Technology
Implementing AI in Drug Discovery
Niklas Sandler and Jukka Corander of Nanoform discuss AI and increasing the likelihood of identifying successful compoundsOnline Exclusives Kristin Brooks, Contract Pharma 02.22.19
-
Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
Evotec & LEO Pharma Partner for Drug Discovery
To generate new leads against innovative targets for a range of dermatological conditions12.04.18
-
Drug Delivery | Drug Development
Traveling Toward the Intersection of Drug Development and Delivery
Overcoming the challenges of delivering drugs to patients.Louise Righton, Global Marketing Operations Manager, 3M Drug Delivery Systems 06.12.18
-
Drug Discovery | Preclinical Outsourcing
Preclinical Partnerships
Bill Barbo of Charles River discusses drug discovery and outsourcing trends in today’s marketOnline Exclusives04.10.18
-
Bio News | Biologics, Proteins, Vaccines | Clinical Trials | Drug Development | Drug Discovery | Industry News | Trials & Filings
Prometic Granted Orphan Drug Designation
For its Inter-Alpha-Inhibitor-Proteins ("IaIp") for the treatment of necrotizing enterocolitis02.15.18
-
Bio News | Breaking News | Clinical Trials | Drug Delivery | Industry News
V ClinBio Acquires 49.98% Stake in Cellix
Will advance Synergix, a transformative pro-drug technology platform02.09.18
-
Bio News | Drug Development | Drug Discovery | Industry News | Trials & Filings
GamaMabs Pharma Receives Orphan Drug Designation
For GM102, a monoclonal antibody targeting AMHR2-expressing tumors02.07.18
-
Clinical Trials | Drug Discovery | Industry News | Trials & Filings
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Industry News | Trials & Filings
EMA Grants Helsinn, MEI Pharma Orphan Drug Designation
For a drug aimed to treat acute myeloid leukemia01.11.18
-
Catalent to Present Industry-centric Topics at AAPS
Will also present 26 scientific posters on a range of topics11.10.17
-
Optimizing Drug Solubility
Selecting excipients for drug solubilization with a new high-throughput screen methodAmjad Alhalaweh, Recipharm 10.11.17
-
Breaking News | Collaborations & Alliances | Drug Discovery | Industry News
Numerate and Takeda Enter Drug Discovery Alliance
Will generate novel clinical candidates using AI-driven drug discovery06.13.17
-
Breaking News | Collaborations & Alliances | Drug Discovery | Industry News | Preclinical Outsourcing
Sanofi and Exscientia Pen €250M Drug Discovery Deal
Initiates collaboration to develop bispecific-small-molecule drugs05.09.17
-
Breaking News | Collaborations & Alliances | Drug Development | Industry News
AstraZeneca, Heptares in Immuno-oncology Pact
Will develop novel immuno-oncology treatments04.10.17
-
Collaborations & Alliances | Drug Development | Drug Discovery | Preclinical Outsourcing
Charles River, Chiesi Extend Drug Discovery Alliance
Will provide integrated drug discovery services to help identify and test Chiesi’s candidates03.13.17
-
Solid Dosage/Semi-solids
Oral Solid Dosage Outsourcing: Trends & Challenges
Despite the increasing number of biologics, oral solids remain the dominant dosage form in the pharmaceutical market.Tim Wright, Editor, Contract Pharma 03.07.17
-
Drug Development | Formulation Development
Modeling & Simulation for Drug Development & Formulation
A look at how to leverage modeling and simulation technology to enhance all phases of the drug development process.Nathan Teuscher and Nikunjkumar Patel , Certara 03.07.17
-
Breaking News | Chemistry | Collaborations & Alliances | Industry News
Ligand Forms Multi-Program LTP Technology Licensing Agreement
Newly-formed Nucorion, co-founded by Ligand, to pursue a pipeline of LTP-based programs for China and other markets07.28.16
-
Capsules | Clinical Trials | Excipients | Formulation Development | Serialization
The Evolution of the ‘One-Stop Shop’ in Clinical Supplies Sourcing
What does a one-stop shop really mean and is it always best for the client?Paul Skultety, Alex McClung, Ted Koontz and Damian Gant, Xcelience, a division of Capsugel Dosage Form Solutions 05.05.16
-
APIs | Capsules | Chemistry | Drug Delivery | Excipients | Formulation Development | Serialization | Supply Chain
Solid Dosage Outsourcing Trends
The market continues to evolve as blockbusters are replaced by more targeted treatments that have unique requirements.Tim Wright, Editor 03.09.16
-
Chemistry | Collaborations & Alliances | Drug Discovery
Domainex and Cresset Form Drug Discovery Alliance
Combine capabilities in chemistry and biology01.26.16
-
Chemistry | Drug Discovery | Formulation Development | Laboratory Testing
Aptuit Initiates Growth Program
To invest $16 million in discovery and CMC capacity and capabilities12.07.15
-
Bioassay Development | Breaking News | Drug Development | GMPs/GCPs | Industry News | Inspections | Methods Development | Process Development | Regulatory Affairs | Toxicology
RXi Pharmaceuticals Receives Orphan Drug Designation
Samcyprone used for the treatment of malignant melanoma stage IIb to IV04.17.15
-
-
Drug Discovery
-
Drug Discovery
-
Biosimilars | Chemistry
-
Aeterna Zentaris Cancer Drug Gets Orphan Drug Designation
Aeterna Zentaris Inc. has received orphan drug designation from the FDA for AEZS-108, a doxorubicin targeted conjugate compound for the treatment of ovarian cancer.05.07.10
-
Breaking News | Trials & Filings
Aeterna Zentaris Cancer Drug Gets Orphan Drug Designation
Aeterna Zentaris Inc. has received orphan drug designation from the FDA for AEZS-108, a doxorubicin targeted conjugate compound for the treatment of ovarian cancer.05.07.10
-
Drug Discovery
-
-
Supply Chain
-
Supply Chain
-
-
Chemistry | Drug Discovery | Toxicology
-
Chemistry | Drug Discovery | R&D | Validation
-
APIs | Chemistry | Clinical Trials | Drug Development
Consolidation in Outsourcing
Our financial analyst sums up 2005's big movesMichael Martorelli 01.24.06
